Biodexa Pharmaceuticals Plc
BDRXNASDAQHealthcare● Active
$3.26
$-0.10(-2.98%)
Market Cap$546888
P/E Ratio—
52W High$66.5
52W Low$2.86
Biodexa Pharmaceuticals Plc (BDRX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BDRX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.01B | $0.00B | $0.01B | $0.00B |
| Gross Profit | ($0.00B) | ($0.01B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Gross Margin %(computed) | — | — | -967.45% | -631.19% | -705.19% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.01B | $0.00B | $0.01B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Operating Income | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Income Tax Expense | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Income | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Net Margin %(computed) | — | — | — | — | -944.64% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-60.00 | $-1157000.00 | $-229000.00 | $-4943000.00 | $-3525000.00 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| EBITDA Margin %(computed) | — | — | — | — | -979.07% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · GBP · B
Explore more Biodexa Pharmaceuticals Plc data
About Biodexa Pharmaceuticals Plc (BDRX) Income Statement
Biodexa Pharmaceuticals Plc (BDRX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BDRX reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.01B) — a net profit margin of —.
Frequently asked questions
BDRX · 4 questionsBiodexa Pharmaceuticals Plc (BDRX) reported revenue of $0.00B for 2025, down —% year-over-year.
BDRX revenueBDRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08